Vascular patent for HealthLinx
Wednesday, 17 September, 2008
HealthLinx [ASX: HTX] has been granted a US patent related to the company's vascular permeability program.
Licensed from the University of Virginia, the patent is related to the inhibition of the p21 activated kinase pathway as a treatment for disorders caused by aberrant vascular permeability.
It has widespread potential applications, including ischemia, stroke or burns.
The patent also forms part of the drug candidate CR014, a potential treatment for acute respiratory distress syndrome (ARDS) that the company is developing with the Canadian-based InSymbiosis.
No effective therapeutic treatments are available for the disease, which has a morbidity rate as high as 40 percent.
HealthLinx and InSymbiosis are preparing to embark on a preclinical development program for CR014.
Bacteriophage cocktail to combat superbugs
Entelli-02 is a five-phage cocktail designed specifically to target Enterobacter cloacae...
Exclusive colostrum intake may reduce risk of food allergies
Newborns who are exclusively fed colostrum in the first 72 hours following birth are five times...
Sunscreen and supplements can lower your vitamin D levels
People who use SPF50+ sunscreen daily are more likely to be vitamin D deficient, while taking...
